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Rhinoviruses are ubiquitous human pathogens of the upper respiratory tract 
and are the major cause of acute exacerbations of asthma and chronic 
obstructive pulmonary disease. At least 160 antigenically distinct serotypes or 
strains have been identified and protective immunity is largely serotype 
specific. Attempts to produce vaccines that induce broad immunity have met 
with limited success which is due in part to this antigenic diversity and a lack of 
information regarding the ideal protective immune responses. Recent 
approaches identifying conserved rhinovirus epitopes and better definitions of 
the immune correlates of protection have raised hope. Here, these newer 
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 Main Text 
After years of neglect, recently there has been renewed interest in a vaccine for 
human rhinoviruses (RVs) [1]. RVs are ubiquitous human pathogens of the upper 
respiratory tract [2] and of the lower respiratory tract in certain pathological 
situations [3]. They are a highly diverse group of viruses with approximately 160 
antigenically and serologically distinct strains or serotypes known to exist [4]. 
Knowledge of what constitutes protective immunity or immunological correlate 
of protection is not completely understood although antibodies (Abs) and in 
particular secretory IgA, are known to protect against re-infection with the same 
serotype [5]. Vaccines that will generate durable humoral immunity against 
antigenically diverse pathogens such as RVs therefore should probably elicit Abs 
that recognize conserved epitopes. Herein lies the extreme challenge with the 
development of a vaccine for RVs. Conserved epitopes are often buried within 
the capsid structure and are therefore not available to neutralising Abs which 
tend to be directed towards surface exposed regions that are hypervariable and 
serotype/strain specific. A successful vaccine must circumvent these challenges. 
Challenges associated with development of RV vaccines. 
 
This commentary will evaluate the historical studies and clinical trials of RV 
vaccines, the current vaccine strategies that have been investigated more 
recently in animal models, the viral features that should be considered to allow 
the generation of broadly protective Abs to RVs. 
  
1. Numerous and evolving groups of antigenically diverse strains 
2. The immune correlate of protection is not fully understood 
3. RV structure shields the conserved epitopes from antibodies 
4. Neutralising antibodies are often serotype specific 
5. Animal models for preclinical evaluation have limitations 
 There are four broad types or groups of infectious disease vaccines that are 
licensed for use in humans. These include; live-attenuated vaccines; inactivated 
vaccines; subunit, recombinant, polysaccharide or conjugate vaccines; toxoid 
vaccines [6]. For RVs, vaccine strategies are limited to live-attenuated, 
inactivated and subunit/recombinant due to the nature of the pathogen. i.e. 
there is no polysaccharide or toxin. In addition, more experimental vaccine 
approaches such as nucleic acid (DNA or RNA) or recombinant vector vaccines 
may be possible but have not been evaluated for RVs or approved for human 
use as yet.  
 
The earliest clinical trials for RV vaccines were performed 40-50 years ago using 
live or formalin inactivated RV serotypes (reviewed in [7]) and found that long 
lasting but only serotype specific immunity was generated to the inoculum. 
Studies by Perkins [8, 9] demonstrated that intranasal immunisation rather than 
intramuscular administration was required to generate nasal secretory Abs 
which were defined as the correlate of protection. However, the failure of these 
approaches to establish broad cross-serotype protection necessitated the 
testing of vaccines containing 10 distinct serotypes (decavalent) that 
unfortunately also provided limited breadth of protection [10]. Recent studies 
immunising macaques expanded the number of serotypes within these 
formulations to 50, but again these could not provide further breadth of 
protective responses other than to the RV serotypes found within the vaccine 
[11]. This multivalent vaccine approach therefore has several deficiencies that 
can explain their limited potential in this setting. The use of formalin inactivated 
RVs is prevalent and is an approach that might be unfavourable for the 
generation of significant immune responses due to the loss of protective 
epitopes. Such inactivated virus formulations will also require the use of 
adjuvants to enhance the vaccine efficacy [12] and many of the early studies did 
not or could not make use of these. It is likely that an appropriate adjuvant that 
can tune the desired immunity for RVs will be required for this approach to be 
more successful [13]. Another issue is that knowledge of exactly what type of 
immunity is necessary for protection to RVs is limited despite vast progress in 
recent years [14]. Although the induction of nasal secretory Abs is thought to be 
necessary, vaccine approaches that generate this immunity are imperfect.  
Lastly the manufacturing process required to produce the desired vaccine 
variability is extremely complicated, especially when considering the increased 
viral titre that would be needed to maintain a small enough dose containing the 
serotype diversity for human administration. It is therefore unlikely that such 
multivalent vaccine preparations will gain clinical relevance. 
A vaccine approach that might have the best chance of success for RVs is to 
identify highly conserved regions and to use these as vaccine antigens in an 
appropriate formulation. This would likely take the form of polypeptides in 
combination with an effective adjuvant. Herein lies the difficulty and challenge 
associated with RVs. Neutralising Abs are thought to interact with exposed 
external regions of the capsid subunits VP1, VP2 and VP3 and to neutralise by a 
variety of mechanisms (reviewed in [15]). In fact neutralising sites have been 
identified in capsid proteins VP1 (NIm-IA, NIm-IB), VP2 (NIm-II) and VP3 (NIm-III) 
for serotypes RV14 and RV2 [16, 17]. These are often discontinuous epitopes 
that form protrusions from the capsid surface and are highly diverse sequences, 
often differing significantly between serotypes. This feature of the known RV 
neutralising epitopes can therefore explain the serotype specificity of 
neutralising Abs. A vaccine with broad RV neutralising potential will need to 
induce a different spectrum of Abs that target regions of the capsid shared by 
numerous serotypes and where binding is still capable of neutralisation. The 
identification of such a unique site is still under investigation but several studies 
have identified potentially exciting candidates. 
Early studies by McCray and Werner [18] found that immunising with peptides 
corresponding to conserved structural regions of VP1 and VP3 from RV14 could 
induce Abs capable of neutralising more than 20 distinct RV serotypes. It is 
unknown why this approach was not pursued further but presumably the use of 
peptide immunogens displayed limitations, as was described later by Barnett et 
al [19] when analysing monoclonal Abs obtained after immunising with a short 
VP2 peptide of RV2. It is unlikely that short peptides will form the correct 3D 
structure similar to complete capsid subunits and therefore the induction of Abs 
capable of binding the intact virion for neutralisation will not occur. 
Nevertheless, a conserved region of VP4 has been identified that shows some 
promise. The N-terminus of VP4 is not surface exposed on the RV capsid but is 
transiently displayed by a process known as capsid breathing and peptide 
immunogens corresponding to this region can induce cross-serotype 
neutralising Abs [20]. However, the physiological role of such Abs in humans has 
not been investigated and the cross-serotype neutralisation induced by VP4 
peptide immunisation was limited to just 2 serotypes which is some way from 
the recognised number of RV serotypes discovered. 
In recent years, immunisation with recombinant capsid proteins of RVs has 
generated cross-serotype immunity. Edylmayr et al [21] produced recombinant 
VP1 of two distinct RV serotypes and demonstrated the production of 
neutralising Abs for additional RV serotypes. However, polyclonal antisera were 
not particularly potent requiring dilutions of less than 1:8 for efficacy in most 
cases. Furthermore, neutralisation activity versus a full spectrum of RV 
serotypes was not evaluated and effects were only seen with four or five strains. 
Additionally, bacterial production of the recombinant capsid proteins is unlikely 
to produce native folded material and the Abs induced will again mostly target 
linear epitopes over the better suited discontinuous epitopes. In the most novel 
RV vaccine approach attempted to date, Glanville et al [22] identified a 
conserved region of the RV polyprotein encompassing VP4 and VP2 (known as 
VP0), generated RV16 VP0 and immunised mice that were subsequently 
challenged with live RV to study protective immune responses in vivo. This was 
the first animal model that allowed for challenge to evaluate RV vaccine 
candidates. Whilst VP0 was immunogenic when combined with a strong 
adjuvant, the generation of neutralising Abs required live RV challenge and was 
restricted to the infecting serotype. Again, suggesting that native capsid 
configurations are needed to induce neutralising Abs. Interestingly, significant 
increases in cross-serotype binding Abs were observed with this approach which 
suggests that a modified prime-boost immunisation regimen might have future 
potential. The most recent study investigating VP0 immunisation has 
determined the immunodominant epitope for Abs corresponds to the 
previously identified NIm-II region of VP2 [23] which helps explain the serotype-
specific neutralisation of this approach. One could envisage that modified 
recombinant capsid variants lacking specific domains of the capsid proteins 
could find utility as inducers of more broadly reactive Abs by removing the 
immunodominance of useful but serotype-specific Ab responses. 
Another difficulty associated with development of a vaccine for RVs is the 
suitability of a small animal model to evaluate candidates and their protective 
abilities in vivo. RVs can infect mice [24] and cotton rats [25] and these have 
been used effectively to evaluate immune responses, pathophysiology of 
infection and vaccine protective responses [24-27], however despite similarities 
to that of humans in many inflammatory parameters, the important marker of 
viral replication is meagre in these models. Until a preclinical model that 
faithfully recapitulates the outcomes of RV infection observed in humans is 
developed, RV vaccine development will continue its relatively slow trajectory. 
In conclusion, investigations of vaccines to generate broad Abs responses to RVs 
are hampered by features of the viral structure, viral mutation and evolution, 
the lack of in-depth knowledge of immune correlates of protection, limited 
availability of preclinical models, and the relative priority placed on this family 
of viruses in the context of human disease. Nevertheless, a universal RV vaccine 
that induces strong protective nasal Abs to conserved epitopes could find utility 
– however discovery of such an epitope shared by 160 viral strains awaits. 
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